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Abstract
Multi-Drug-Resistance (MDR) efflux pumps have been increasingly reported in
Gram negative and Gram positive bacteria. These efflux mechanisms pump out a wide
variety of structurally unrelated antimicrobials thus leading to reduced susceptibility due
to lowered intracellular concentrations. The activity of such antimicrobials can be
restored by the inhibition of the multi-drug efflux pumps. Several MDR pump inhibitors
which inhibit the efflux mechanisms in bacteria have been identified. Reserpine and
verapamil are two such inhibitors showing considerable effects on the MDR pumps. But
the concentrations required to achieve these effects are too high to be clinically relevant.
Reserpine has adverse effects such as neurotoxicity. The identification and development
of safe and effective inhibitors of bacterial efflux pumps is needed. Crude leaf extracts of
goldenseal (Hydrastis canadensis) have been shown to have such effects.
This dissertation researches the MDR pump inhibitory activity of goldenseal leaf
extract and the separation of its constituents. First, three forms of goldenseal samples
supplied by the Sleepy Hollow Farm, GA were evaluated for their antimicrobial
properties. Minimum inhibitory concentration (MIC) of all different forms of goldenseal
i.e, powders, liquid extracts, and retention solids, in five different ratios of root/leaf
combinations was determined against MDR bacterial strains of Staphylococcus aureus
and Campylobacter jejuni. The antimicrobial activity of goldenseal samples was also
determined against human intestinal beneficial bacteria, Lactobacillus acidophilus.
Goldenseal liquid extracts were found to have high activity against the MDR bacteria
while showing minimum impacts on the viability of L. acidophilus.
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Second, goldenseal leaf extract was assayed for its MDR efflux pump inhibitory
activity against MDR pumps belonging to different pump superfamilies in both S. aureus
and C. jejuni. Goldenseal increased the potency of different antimicrobials against the
MDR bacteria when combined in sub lethal doses (≤ 0.5MIC) by exerting at least a 2-fold
reduction in MICs of antimicrobials against S. aureus strains and a 16-fold reduction
against C. jejuni strain. Quantitative real-time RT-PCR and ethidium bromide
uptake/efflux studies indicated that goldenseal leaf extract represses the genes encoding
these MDR pumps in both bacterial systems.
Finally, five active bands exhibiting potential MDR efflux pump inhibitory
activity were identified in thin layer chromatography and bioautographic studies. The
identity of these bands could not be established by GC/MS which might be due to the
volatility of the compound. LC/MS analysis led to a list of possible compounds in these
active bands. In conclusion, the results of this work indicate that one or more constituents
in goldenseal leaf extract exhibit MDR efflux pump inhibitory activity.
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Chapter 1
Literature Review

1.1

Antibiotic Resistance:
Antibiotics are substances that kill bacteria or prevent their reproduction. Since

their discovery in the 1940’s, use of antibiotics has led to possible treatment of many
bacterial infections that once killed millions. Between 1940’s and 1970’s life expectancy
rate increased by 8 years and, much of it has been attributed to antibiotics (Riley, 2001).
Penicillin, the first introduced antibiotic discovered by Sir Alexander Fleming, was used
to effectively treat Streptococcus pneumonia infections during the World War II.
Resistance to antibiotics was observed in bacteria soon after their introduction as
chemotherapeutic agents against bacterial infections. Antibiotic resistant bacteria are
defined as the strains of bacteria that can grow and divide normally in the presence of an
antibiotic that should kill or inhibit their growth. In 1967 the first penicillin-resistant S.
pneumoniae was observed in Australia, and seven years later in USA, another case of
penicillin-resistant S. pneumoniae was observed in a patient with pneumococcal
meningitis (Doern, 2001). This trend was observed with other bacteria and antibiotics.
Tetracycline resistance by normal human intestinal flora increased from 2% in the 1950s
to 80% in the 1990s. Kanamycin, an antibiotic used in the 1950s, became clinically
useless as a result of the prevalence of kanamycin-resistant bacteria (Shoemaker, 2001).
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1.2

Mechanisms of Antibiotic Resistance:
Bacteria develop resistance to antimicrobials by various mechanisms which

include: change in metabolic pathways, (Hancock 1997, 1998), production of enzymes
which inactivate the agents (Thomson and Smith, 2000), alteration of target sites
(Hooper, 2000) and active efflux from cells (Poole, 2000).
Many mechanisms with which bacteria utilize to defend themselves from
antibiotics are depicted in Figure1.1. The four major mechanisms of antibiotic resistance
are drug inactivation or modification, alteration of target site, metabolic pathway
modification and efflux pumps.
Drug inactivation or modification by the production of antibiotic degrading
enzymes is the best known mechanism. Examples for this are the β-lactamases which
cleave the β-lactam ring in the penicillin rendering it inactive. Around 200 β-lactamases
have been isolated and these are wide spread in most bacteria and show varying degrees
of resistance to β-lactamase inhibitors, such as clavulanic acid (Livermore, 1995).
Alteration of target site, which becomes resistant to inhibition by the antibiotic
while continuing to produce the initial sensitive target, is the second mechanism. This
allows bacteria to survive in the face of selection; the alternative enzyme “bypasses” the
effect of the antibiotic. An example is the alternative penicillin binding protein (PBP2a),
which is produced in addition to the normal penicillin binding proteins by methicillin
resistant Staphylococcus aureus (MRSA). This protein is encoded by the mecA gene, and
because PBP2a is not inhibited by antibiotics such as penicillin, the cell continues to
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synthesize peptidoglycan and hence has a structurally sound cell wall (Michel, Gutmann,
1997).

Figure 1.1: Antibiotic resistance mechanism: (Hawkey, 1998)

Metabolic pathway modification is another resistance mechanism which bacteria
exhibit. Sulfonamides inhibit the enzyme dihydropterate synthetase of bacteria which acts
upon para-aminobenzoic acid, a precursor of folic acid. This enzyme is not found in
mammalian cells. This makes sulfonamides a better choice for treatment of bacterial
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infections. Resistance is developed by the bacteria by their utilizing preformed folic acid
like mammalian cells (Beneveniste, Davies, 1973).
All living cells express multidrug efflux transporters as surface proteins which
recognize a wide range of structurally dissimilar hydrophobic organic compounds and
extrude them from the cytoplasm into the outer medium (Ambudkar, 1999, Putman,
2000, Georgiev, 2000). Resistant bacteria overexpress such pumps or work in synergy
with other factors (Jun Lin, 2003). Examples of such pumps are NorA in S. aureus and
CmeABC in C. jejuni. Substrates for these pumps include various anti cancer and
antimicrobial agents.
1.3

Multi-Drug-Resistance Efflux Pumps:
Multi-drug-resistance (MDR) is defined as the ability of bacteria to show

resistance against structurally different compounds. A simple error in the DNA
replication could lead to MDR. But such small mutations do not explain the rate at which
the MDR spreads through generations, as the mutation occur at low frequencies and is
due to a change on the chromosome. The rapid spread of MDR has been attributed to
plasmid transfer (Kruse, 1996).
Resistance due to MDR efflux pumps has been widely reported in the last two
decades (Lewis, 1994, Nikaido, 1994), since P-glycoprotein was first identified by R. L.
Juliano and V. Ling. Unlike other resistance genes which are either plasmid encoded or
specific for a given antibiotic and which are acquired through horizontal gene transfer,
the genes for efflux pumps are found in all living things. Efflux pumps prevent the
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accumulation of antibiotics by pumping them out of the cell. These efflux pumps are
modified transport proteins present on the cell membrane which form solute-specific
channels or transport pathways (Nikaido, Saier Jr, 1992).
The MDR pumps have been found to be homologous to regular, substrate-specific
transporters. The MDR pumps Bmr, Blt and NorA of Gram positive bacteria share a
higher sequence similarity with tetracycline transporters TetA, B and C of Gram negative
bacteria than with other MDR pumps belonging to the same family. Hence it is evident
that drastic changes in the transporter structure are not required for these MDR pumps to
acquire the ability to recognize multiple compounds. This can be further proved by the
fact that pumps of different families share similarity in substrates, for example a major
facilitator Bmr and an ABC transporter P-glycoprotein recognize largely overlapping
spectra of substrates and share many common inhibitors like reserpine (Neyfakh, 1991).
Co-existence of multiple mechanisms of resistance to a particular antibiotic in a
single bacterial cell has been demonstrated in several bacteria. A single cell may also
contain more than one efflux pump capable of efflux of the same antibiotic. Escherichia
coli or Pseudomonas aeruginosa despite the presence of endogenous MDR pumps
(AcrAB-TolC and MexAB-OprM, respectively) in their genome may acquire plasmidencoded transporters such as TetA or CmlA through mutation, which can also transport
tetracycline and chloramphenicol (Nikaido, 1998, Poole, 2000). P. aeruginosa contains
multiple MDR pumps that can confer resistance to fluoroquinolones (Lomovskaya,
2000).
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1.4

Multi-Drug Efflux Pump Classification:
MDR pumps are classified into five families: ATP binding cassette (ABC)

(Lubelski, 2007), major facilitator super family (MFS) (Law, 2008), resistance nodulation
cell division (RND) (Tseng, 1999), small multidrug resistance (SMR) (Chung & Saier,
2001) and multidrug and toxic compound extrusion (MATE) (Moriyama, 2008). A
characterization of these pumps is shown in Figure 1.2. All of these families are energy
dependent active drug efflux transporters and utilize energy through either ATP or proton
motive force (PMF) (Paulsen, 1998,). ABC transporters are dependent on ATP hydrolysis
(primary active transporters), MFS, RND and SMR are proton-driven efflux pumps and
MATE transporters consist of a Na+/H+ drug antiporter system (secondary active
transporters). Examples of MDR efflux pumps in Gram positive and Gram negative
bacteria are given in Figure 1.3.

Figure 1.2: Representative members of the five characterized families of multidrug
efflux pumps (Paulsen, 2003)
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1.5

Multi-Drug Efflux Pump Structure:

Primary Active Transporters:
Crystallization of the ABC proteins has proved difficult but electron microscopic
studies of single particles and 2D crystals have provided low-resolution structural
information. This structural information elucidates a hexagonal ring of protein with a
central asymmetrical pore (Borges-Walmsley, McKeegan, 2003).

Figure 1.3: MDR pumps in Gram positive and Gram negative bacteria (Piddock, 2006)
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Secondary Active Transporters:
The structure of the secondary active transporters differs from one another. MFS
transporters are typically composed of approximately 400 amino acids that are putatively
arranged into 12 membrane-spanning helices, with a large cytoplasmic loop between
helices six and seven (Saier, 1999). RND transporters are much larger than MFS
transporters, being composed of approximately 1000 amino acid residues (Tseng, 2003).
Unlike MFS transporters, they possess large periplasmic or extracytoplasmic domains
between helices 1 and 2 and between helices 7 and 8 (Murakami, 2003). SMR
transporters are much smaller than those belonging to the MFS and RND families. SMR
pumps are normally composed of around 100 amino acids that are putatively arranged
into four helices (Paulsen, 1996). MATE transporters are similar in size to the MFS
transporters, and are typically composed of approximately 450 amino acids which are
putatively arranged into 12 helices; however, they do not have any sequence similarity to
members of the MFS transporters (Jack, 2001).
Efflux pumps are differentiated based on the number of components they possess,
which also determines the extrusion of antibiotics from the cell. Single component efflux
pumps such as TetA extrude the antibiotic into the periplasmic membrane which results
in maintaining a concentration gradient across the inner membrane (Thanassi, 1997).
Two-component efflux pumps such as TolC, AcrA and AcrB, have a transporter which
brings the two components together thus allowing extrusion of antibiotics into the
external medium (Zgurskaya and Nikaido 1999a; Zgurskaya and Nikaido, 1999b). This
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results in a concentration gradient across the outer membrane and decreases in antibiotic
levels in the periplasmic membrane.
Over expression of these MDR pumps has led to the development of drug
resistant tumor and bacterial and fungal infections. Inhibition of these pumps can lead to
increased drug sensitivity and provides a new approach to overcome multidrug resistance.
Due to emergence of resistance to all classes of antibiotics, in particular the
fluoroquinolones, significant interest has been shown on MDR pump inhibitors.
One approach of overcoming resistance by MDR efflux pumps is the
development of derivatives of existing antibiotics which are minimally affected by the
efflux pumps. Examples of this are the glycylcyclines (Sum, 1998), a new class of semisynthetic tetracyclines which overcome MDR efflux pumps. The glycylcyclines are not
recognized by the transporter proteins (Someya, 1995).
1.6

Efflux Pump Inhibitors:
Another approach for overcoming resistance due to MDR efflux pumps is the

inhibition of these MDR efflux pumps by Efflux Pump Inhibitors (EPIs). In the present
market there are no EPIs that can be used in combination with a drug that is a pump
substrate to increase its activity. The concept of using a compound that inhibits resistance
together with a conventional antibiotic is well proven (Esposito, Noviello, 1990). Several
MDR pump inhibitors which inhibit the efflux mechanisms have been identified. Several
factors such as appropriate potency and spectrum of activity, bioavailability, clearance,
avoidance of mechanism-based and/or non-mechanism based toxicity need to be
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considered when developing a new infectious disease drug. Development of an EPI will
most obviously result in a combination therapy.
In the selection of an effective EPI, several criteria should be considered:
•

Determining the selectivity of the EPI should be the foremost criteria to be
ascertained. As mentioned earlier five families of MDR pumps have been
identified and representatives of each family are present in both eukaryotic and
prokaryotic cells and an EPI which would not be selective to specific pumps is
best desired.

•

MDR efflux pumps though belonging to different families extrude similar
antibiotics; hence it maybe possible to identify a single EPI which would target
several relevant transporters.

•

MDR efflux pumps extrude structurally dissimilar compounds, so a random
screening process is a more practical approach in initial designing of an EPI.

MDR efflux pump inhibition by several synthetic chemical compounds has been
demonstrated by various investigators. A library of 9600 synthetic molecules was
screened against NorA pump yielded in about 4% of the coumpounds showing activity
(Markham, 1999). All the coumpounds showed a 4-fold decrease in the MIC of
ciprofloxacin in strains of S. aureus over expressing the NorA pump. Another synthetic
compound MC-207 screened from a library of 200,000 synthetic compounds decreased
the intrinsic resistance to levofloxacin, an. 8-fold, in a wild type strain of P. aeruginosa,
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while in strains over-expressing efflux pumps the susceptibility was increased up to 64fold (Lomovskaya, 2001).
Screening

of

85,000

Streptomyces

fermentations

has

resulted

in

the

characterization of two new natural product EPIs, EA-371a and EA-371d (Lee, 2001).
Both compounds caused a 4-fold reduction in the MIC of levofloxacin effluxed by the
MexAB-OprM pump in P. aeruginosa.
1.7

Plants as sources for EPIs:
Reserpine is an antihypertensive plant alkaloid isolated from the roots of

Rauwolfia vomitoria Afz (Poisson, 1954). Reserpine has been demonstrated to show
activity against the Bmr efflux pump; this pump mediates tetracycline efflux in Bacillus
subtilis (Neyfakh, 1991). 5′-methoxyhydnocarpin, isolated from Berberis fremontii,
decreases the antimicrobial actvity of ciprofloxacin on NorA expressing strains of S.
aureus (Sterimitz, 2000).
There are many reasons for searching the plant world for possible EPIs; a few of
them are listed below:
•

Soil is rich in microflora with bacteria, fungi and viruses, so it is rational to
assume that plants produce several antimicrobials as part of their defense. Several
bacterial species found in the soil are taxonomically similar to pathogenic
bacteria; hence this relation could be further explored.
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•

25% of prescription drugs and 60% of anticancer and antibiotics owe their origin
directly or indirectly to natural products (Gibbons, 2008). This makes
phytochemicals as natural products highly valuable as bioactive compounds.

•

Due to their difference in structures from microbial derivatives, phytochemicals
might show a different mode of action distinct from the existing antibiotics.

•

There are several instances in history where plants have been used to treat varied
ailments, Echinacea, St. John’s Wort, Ginseng etc, are a few examples.

1.8

Hydrastis canadensis:
Goldenseal

(Hydrastis

canadensis)

(Figure1.4)

belongs

to

the

family

Ranunculaceae. It is a small hairy perennial which emerges in early spring (mid-March to
early May) and dies back in mid-August to mid-September. The natural range of the plant
extends from southern New England west through the extreme southwestern portion of
southern Ontario, to southern Wisconsin, and south to Arkansas and northern Georgia
(Figure 1.5) (USDA page for plant profile).

Figure 1.4: Hydrastine Canadensis (Goldenseal)
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Historically, Native Americans have used goldenseal for various health conditions
including skin diseases, ulcers, and gonorrhea. Its roots and rhizomes, which internally
are bright yellow in color, have been used as a traditional medicine for the treatment of
infection, inflammation, and as an immune system booster (Edwards, Draper, 2003).
More recently it is known to be taken orally to treat upper respiratory infections
and gastrointestinal tract disorders, and is commonly found in commercial products in
combination with Echinacea purpurea (Borchers, 2000, Scazzocchio, 1998, Schieffer,
2002). Modern herbalists consider it an alternative anti-catarrhal, anti-inflammatory,
antiseptic, astringent, bitter tonic, laxative, and muscular stimulant (Grieve, 1971, Mills,
2000, Birdall, 1997). Goldenseal has also been evaluated for its activity against MDR
Mycobacterium tuberculosis (Gentry 1998). An increase in the primary IgM response
was noticed in rats injected with the antigen keyhole limpet hemocyanin, on
administration of goldenseal root powder (Maisel, 1999). It has been demonstrated as
natural LDL-lowering agent (Abidi, 2006).
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Figure 1.5: Distribution of Hydrastis canadensis (USDA, Plant Profile 2009)

1.9

Chemical composition of Goldenseal:
The National Toxicology Program is currently investigating the toxicology of

goldenseal root powder. A rapid ambient extraction method to assay goldenseal root
powder and determine its purity has been developed (Weber, 2003). The main
components of goldenseal are its alkaloids: berberine, hydrastine and canadine (Figure
1.6). It also possesses secondary metabolites such as protoanemonin and glycosides.
Berberastine, meconin, chlorogenic acid, phytosterins, resins, albumin, starch, sugars,
lignin, and volatile oil (in the root) are other compounds found in addition in goldenseal
(Van Berkel, 2007).
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a

b

c

Figure 1.6: Structures of alkaloids present in goldenseal, (a) berberine, (b) canadine and
(c) hydrastine

Berberine extracts and salts have been demonstrated to inhibit intestinal parasites
like Giardia lamblia, Entamoeba histolytica, Trichomonas vaginalis, (Kaneda. Y 1990)
and Leishmania donovani (Abidi, 2005). Crude extracts were more effective than
berberine salts (Kong, 2004). Berberine provides the yellow color to the root and
rhizome, hence the name “Yellow Root” for goldenseal.
The other major alkaloid components are canadine and hydrastine. Canadine is
known for its sedative and muscle relaxant properties. Hydrastine is a valuable drug in
the treatment of diseases of the skin. Both of them are taken internally into the body or as
a topical application. Hydrastine is especially useful as a stomachic tonic, and as a
hepatic stimulant in cutaneous infections. Better activity is exhibited when hydrastine is
used as a topical application than taken internally (Beckstrom-Sternberg, 1997).
Two new C-methyl flavonoids, 6, 8-di- C-methylluteolin 7-methyl ether and 6- Cmethylluteolin 7-methyl ether have been isolated and these show activity against oral
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pathogens such as Streptococcus mutans and Fusobacterium nucleatum (Hwang, 2003).
Quinic acid feruloyl esters have also been identified and their activities against
Mycobacterium tuberculosis have been evaluated, but have been shown not to have a
significant effect (Gentry, 1999).
1.10

Objectives
The long term goal of this project is to develop therapies combining antimicrobial

agents and MDR inhibitors to enhance the activities of antimicrobial agents, reduce the
side effects associated with the use of antibiotics, and minimize the emergence of MDR
pathogens. The main objectives of this project are:
1. Determine the antimicrobial activity of different forms of goldenseal on
Staphylococcus aureus and its effect on beneficial bacteria
2. Determine the efflux pump inhibitory activity of goldenseal leaf extract on
different families of efflux pumps in Gram negative and Gram positive bacteria
3. Separation and identification of goldenseal leaf extract constituents
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Chapter 2

Antimicrobial Activity of Hydrastis canadensis (Goldenseal)

2.1

Introduction

Initially available only in specialty health and natural foods stores, goldenseal
became part of the general marketplace during the 1990s, and since then the demand has
been increased dramatically (Foster, 2000). Between 1991 and 1996, the wholesale value
of goldenseal in the U.S. increased by as much as 600% (Robbins, 1996). Since 1994
goldenseal has been one of the top six best-selling medicinal herbs in the U.S. (Robbins,
1996; Small and Catling, 1999), and remains so today (Foster, 2000). Between 1995 and
1997, the medicinal plant market as a whole, as well as demand for goldenseal,
experienced in excess of a 30% growth rate (USFWS, 1997). Goldenseal is also available
in numerous drug products (Small and Catling, 1999) and in a wide array of herbal
products on international markets, e.g., in China, France, Australia, Germany, United
Kingdom, Italy, and other European countries (IUCN, 1997; Robbins, 1996). Since
demand has increased greatly, and supplies have declined, the price of goldenseal has
increased dramatically.
Presently, the quality of the goldenseal samples in the market is analyzed by
methods developed by two groups: Genest and Hughes and those described by Wagner
and Bladt (Govindan, 2000). But these methods check for adulteration and for the
presence or absence of berberine. To develop research grade goldenseal, a more thorough
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analysis, which involves testing of the sample goldenseal on different pathogens and
beneficial bacteria, is required.
The goldenseal samples for this work were supplied by the Sleepy Hollow Farm
in Georgia. A brief description of the samples provided is given in Table 2.1.
Table 2.1: List of samples provided by Sleepy Hollow Farm
Sample
Liquid Extracts

Description
60% grain alcohol extracts. Supplied in
different ratios and combinations
Dried, ground powder. Supplied in different
Powders
ratios and combinations
Retention Solids Solids obtained from retention of the liquid
extracts by evaporation.

Components
Root and rhizome
Leaf and Stem
Root and rhizome
Leaf and stem
Root and rhizome
Leaf and stem

The primary objective of this study was to determine the antimicrobial
characteristics of the various goldenseal preparations on MDR S. aureus, C. jejuni strains
and beneficial bacteria existing as a normal gut flora of the human body such as
Lactobacillsc acidophilus.

2.2
2.2.1

Materials and Methods

Bacterial Strains:
The MDR strains selected for these studies were the NorA MDR pump over

expresser strain: SA1199B and its wild type counterpart SA1199 donated by Dr. Glenn
Kaatz. Lactobacillus acidophilus (ATCC 53544) strain was obtained from American
Type Culture Collection. S. aureus strains were maintained in Mueller Hinton II (BD-
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Difco) medium at 35°C under aerobic conditions. L. acidophilus 53544 was maintained
in MRS medium (BD-Difco) at 37°C with 5% CO2.
2.2.2

Goldenseal Samples:
The goldenseal samples were provided by the Sleepy Hollow Farm, GA as listed

in Table 2.1. The liquid extracts and retention solids were lyophilized to determine the
dry weight.
2.2.3

Antimicrobial Assay:
The Minimum inhibitory concentration (MIC) of the liquid extract and powder

samples of goldenseal was determined by using the microbroth assay as described by the
Clinical and Laboratory Standards Institute (CLSI). The antimicrobial is added in twofold dilutions in triplicates to round bottomed 96 well plate and each well is seeded with
105 cell/ml in MH II broth (final volume in each well is 200µL). The plates are incubated
aerobically at 35°C for 18-24hrs and observed for visual growth. MIC is determined as
the lowest concentration of the antimicrobial with no visible growth. The assays were
performed twice in triplicates.
Due to nature of the powder samples which would not make it possible to observe
the growth in the wells of the 96 well plate, macrobroth technique is applied. The
samples of goldenseal and bacteria were scaled up to a volume of 5mL. The tubes were
incubated in a shaker incubator at 35°C for 18-24hrs under aerobic conditions. The tubes
were taken out of the incubator and observed for turbidity after allowing the powders to
settle.
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Minimum bactericidal concentration (MBC) was determined by taking the
inoculums (100µL) from the wells in the microbroth assay and resuspending in fresh
liquid and solid MH II medium. The agar and broth was incubated aerobically at 35°C for
18-24hrs and observed for growth. MBC is defined as the lowest concentration which
would not give rise to any growth. All assays were performed twice in triplicates. For all
the assays berberine sulfate was used as standard for comparison.

2.3

Results

The MIC and MBC of the goldenseal samples and berberine sulfate are displayed
in Table 2.2. Among the three different combinations, liquid extracts yielded the best
results. The liquid samples are achieved by the extraction of the root or stem of
goldenseal in 60% grain alcohol at the Sleepy Hollow farm. Of the different preparations
of the liquid extracts (mixtures consisting of different root/leaf ratio combinations); the
2:2 R/L preparations has shown the maximum effect on the MDR S. aureus: SA1199B.
The powders had a very high MIC values against the S. aureus strains, which was
expected as the samples had more solid material than the others. The retention solids had
comparatively moderate effect on the bacteria. But retention solids were supplied as thick
paste of root or leaf, which when diluted to make the different ratios formed suspensions.
The suspensions had to be shaken vigorously each time sample had to be taken, thus
leading to the contributable inconsistency in the amount taken.
The MBCs of the powder samples were twice the MIC values and there is no
difference in the MIC and MBC of the retention solids. The MBCs of the liquid extracts
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are slightly different than their MIC. The MIC and MBC of the extracts on the over
expresser SA1199B are the same as the MICs. The MBC of the 4:0, 3:1 and 0:4 R/L
preparations on the wild type SA1199 are the same, while the MBC of 2:2 and 1:3 R/L
preparations are twice that of MIC.
The MIC of goldenseal samples on L. acidophilus 53544 was much higher in
comparison the MIC to that on the S.aureus. The MIC of different liquid extract
prparations on L. acidophilus was greater than 2mg/mL, that of powder samples greater
than 10mg/mL and that of retention solids greater than 2mg/mL.
Table 2.2: MIC and MBC of all goldenseal samples on S. aureus SA1199 and SA1199B
and L. acidophilus
Goldenseal sample
Root/Leaf
Powders
4:0
3:1
2:2
1:3
0:4
Liquid Extracts
4:0
3:1
2:2
1:3
0:4
Retention solids
4:0
3:1
2:2
1:3
0:4
Berberine sulfate

SA1199
MIC

MBC

SA1199B
MIC

MBC

5mg/mL
5mg/mL
5mg/mL
5mg/mL
5mg/mL

10mg/mL
10mg/mL
10mg/mL
10mg/mL
10mg/mL

5mg/mL
5mg/mL
5mg/mL
5mg/mL
5mg/mL

10mg/mL
10mg/mL
10mg/mL
10mg/mL
10mg/mL

250µg/mL
250µg/mL
250µg/mL
500µg/mL
1000µg/mL

250µg/mL
250µg/mL
500µg/mL
1000µg/mL
1000µg/mL

500µg/mL
500µg/mL
500µg/mL
1000µg/mL
1000µg/mL

500µg/mL
500µg/mL
500µg/mL
1000µg/mL
1000µg/mL

625 µg/mL
625 µg/mL
1250µg/mL
1250µg/mL
1250µg/mL
125µg/mL

625 µg/mL
625 µg/mL
1250µg/mL
1250µg/mL
1250µg/mL
125µg/mL

625 µg/mL
1250 µg/mL
1250µg/mL
1250µg/mL
1250µg/mL
250µg/mL

625 µg/mL
1250 µg/mL
1250 µg/mL
1250 µg/mL
1250 µg/mL
250µg/mL
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L. acidophilus
MIC
MBC

>5mg/ml

>2000µg/mL

>2000µg/mL

250µg/mL

The goldenseal samples were analyzed by the Sleepy Hollow Farm for the
percentage of different constituents in them. Table 2.3 shows an interpretive of all the
constituents in the liquid extracts.

Table 2.3: Percentage of berberine and hydrastine in the goldenseal liquid extracts
R/L Ratio
4:0

Berberine
mg/ml
1.53

Hydrastine
mg/ml
1.11

Percentage of
Grain alcohol
53.00

Dry Weight
mg/ml
8 mg/ml

Berberine
%
19.13

Hydrastine
%
13.875

3:1

1.32

1.03

54.50

10 mg/ml

13.20

10.3

2:2

1.1

0.95

56.00

10 mg/ml

11.00

9.50

1:3

0.89

0.87

57.50

11 mg/ml

8.09

7.91

0:4

0.67

0.79

59.00

13 mg/ml

5.15

6.08

The MIC of berberine sulfate on the NorA over expresser strains SA1199B and L.
acidophilus is 250µg/mL. Using the interpretive Table 2.3 the concentration of each
liquid extract sample was calculated (Table 2.4). When the 2:2 R/L liquid extract
preparation is taken into consideration, the MIC of this sample showed best antimicrobial
activity on SA1199B (500µg/mL). The berberine content in this sample was calculated to
be about 55µg/mL, almost one fifth of the MIC of pure berberine sulfate. This
observation leads to the speculation that an unknown component(s) in the extract acts in
synergy with berberine thus lowering its MIC.
When tested against SA1199B, of all the liquid extracts tested the lowest
concentration of berberine was determined to be in the leaf extract (0:4 R/L) preparation.
This berberine level (51.50µg/mL) is much lower than the berberine level in the root
extract (95.65µg/mL). This indicates that the highest activity (if present) of the unknown
component is present in the leaf extract.
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Table 2.4: MIC of goldenseal liquid extracts on different bacterial strains (the amount of
equivalent berberine in each sample is given in the parenthesis
R/L Ratio

SA1199 (wildtype)
250 µg/ml
(= 47.83µg/ml
berberine)

SA1199B (MDR)

3:1

250 µg/ml
(= 33.00 µg/ml
berberine)

500 µg/ml
(= 66.00 µg/ml
berberine)

2:2

250 µg/ml
(= 27.50 µg/ml
berberine)

500 µg/ml
(= 55.00 µg/ml
berberine)

1:3

500 µg/ml
(= 40.45 µg/ml
berberine)

1000 µg/ml
(= 80.90 µg/ml
berberine)

0:4

1000 µg/ml
(= 51.50 µg/ml
berberine)

1000 µg/ml
(= 51.50 µg/ml
berberine)

Berberine
sulfate

125µg/mL

250µg/mL

4:0

500 µg/ml
(= 95.65µg/ml
berberine)

2.4

C.jejuni
81-176
31.25 µg/ml

(=5.98µg/mL
beberine)
31.25 µg/ml
(=4.125µg/mL
beberine)
31.25 µg/ml
(=3.44µg/mL
beberine)
62.5 µg/ml
(=5.05µg/mL
beberine)
62.5 µg/ml
(=3.2µg/mL
beberine)
8µg/mL

L. acidophilus
53544
> 2 mg/ml
(> 382.60 µg/ml
berberine)
> 2 mg/ml
(> 264.00 µg/ml
berberine)
> 2 mg/ml
(> 220.00 µg/ml
berberine)
> 2 mg/ml
(> 161.8 µg/ml
berberine)
> 2 mg/ml
(> 103 µg/ml
berberine)
250µg/mL

Discussion

The results of the antimicrobial assay clearly indicate that the liquid extracts are
much more effective on the S. aureus than the other forms of goldenseal. This might be
due the fact that the grain alcohol has extracted the components responsible for the
antimicrobial activity. Hence the liquid extracts are best form that can be projected for
antimicrobial effect. The hisher antimicrobial activity of goldenseal leaf extract on L.
acidophilus clearly indicates that the human beneficial strain was less susceptible to the
antimicrobial activity of goldenseal than the S. aureus strains. This finding is favorable

23

since if goldenseal is administered as antimicrobial agent, the minimal the impact on the
normal microflora is desirable.
When tested against SA1199B, of all the liquid extracts tested the lowest
concentration of berberine was determined to be in the leaf extract (0:4 R/L) preparation.
This berberine level (51.50µg/mL) is much lower than the berberine level in the root
extract (95.65µg/mL). This indicates that the highest activity (if present) of the unknown
component is present in the leaf extract. The other alkaloids in the extracts, hydrastine
and canadine have not been reported to have much antimicrobial activity. Hence it is safe
to assume that berberine is responsible for the antimicrobial activity of goldenseal
extracts
The SA1199B strain used for this study, over expresses the NorA MDR efflux
pump (Kaatz, 1991). The natural substrates for NorA pump include berberine,
ciprofloxacin and ethidium bromide. Similarly the CmeABC pump in C. jejuni extrudes
the antimicrobials like ciprofloxacin and ethidium bromide. Goldenseal leaf extract has
exhibited antimicrobial property against these strains which when compared to the
equivalent concentration of berberine in it, is much lower. The leaf extract as discussed
earlier might consist of unknown component(s) that lower(s) the MIC of berberine in
synergy and could be used as a potential MDR EPI.
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Chapter 3

Effect of Goldenseal Leaf Extract on MDR Pumps in Staphylococcus
aurous and Campylobacter jejuni

3.1
3.1.1

Introduction

Staphylococcus aureus
Species of the genus Staphylococcus cause a range of suppurative (pus-forming)

diseases in humans and other animals. Staphylococci are Gram positive cocci and are
characteristically nonmotile, catalase positive facultative anaerobes that grow in grapelike clusters. The genera are also divided into coagulase positive and coagulase negative
based on whether the bacteria can produce the enzyme coagulase, which clots the
fibrinogen in blood. Staphylococcus aureus, the most invasive species, is coagulase
positive and often produces a yellow carotenoid pigment, hence the name 'golden staph'.
S. aureus causes acute to chronic infections, such as boils, deep tissue abscesses,
enterocolitis, bacteriuria, osteomyelitis, pneumonia, carditis, meningitis, septicemia and
arthritis. Coagulase negative species, such as Staphylococcus epidermidis, are
opportunistic pathogens that although generally less invasive, are increasingly associated
with serious infections (Von Eiff, 2002).
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3.1.2

Methicillin Resistant S. aureus (MRSA):
S. aureus was first proposed to be a major cause of wound suppuration by Sir

Alexander Ogston (Ogston,1883) and Skinner and Keefer reported in 1941 that the
mortality rate associated with S. aureus bacteremia in 122 patients at the Boston City
Hospital was 82% (Skinner, Keefer, 1941). The discovery of penicillin by Sir Alexander
Fleming led to the management of S. aureus infections but incidence of penicillin
resistant S. aureus (PRSA) started emerging in the mid 1940’s. Introduction of
methicillin in 1959 resulted in a general decline of pandemic phage-type 80/81 S. aureus,
the strain responsible for the infections in hospitals and community. In two years,
however, methicillin resistant S. aureus (MRSA) was isolated (Jevons, 1964) and, slowly,
reports of small clusters started appearing. A general timeline of the emergence of
resistant S. aureus is given in Figure 3.1.

Figure 3.1: Timeline in years of emergence of antibiotic-resistant S. aureus, epidemic,
and estimated deaths caused by MRSA in the United States. Arrows indicate
approximate length of time for each pandemic/epidemic. (DeLeo, 2009)
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In the United States, the numbers of hospitalizations due to S. aureus are 292,000
of which 40% are caused by MRSA (Kuehnert, 2005). These infections have now been
given the status of the number one cause of hospital acquired (HA MRSA) infections
(DeLeo, 2009). Between the late 1970s and early 1980s and continuing to present day,
there has been a growing incidence of hospital-associated (nosocomial) and also
community-acquired (CA MRSA) infections caused by strains of S. aureus (Slade, 2009).
MRSA infections in USA intensive-care units rose from 2% in 1974, to 22% in 1995 and
64% in 2004 (Klevens, 2006). Community acquired infections were initially caused by
methicillin sensitive S. aureus (MSSA), but CA MRSA fast emerged and it now occurs
worldwide (Chambers, 2001).
3.1.3

Pathogenesis of S. aureus:

Those infections or syndromes caused by S. aureus are listed in Tables 3.1. There are five
stages in the pathogenesis of S. aureus infections: colonization, local infection, systemic
dissemination and/or sepsis, metastatic infection, and toxinosis. Approximately 30% of
humans are asymptomatic nasal carriers of S. aureus (Archer, 1998) carrying it in their
anterior nares, such that in these individuals S. aureus is part of the normal flora. S.
aureus carriers are at higher risk of infection and are presumed to be an important source
of the S. aureus strains that spread among individuals. The primary mode of transmission
of S. aureus is by direct contact, usually skin-to-skin contact with a colonized or infected
individual, although contact with contaminated objects and surfaces might also have a
role. Local abscesses of skin or skin structures result when the organism is inoculated
into the skin from a site of carriage. The infection can spread locally (e.g., carbuncle,
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cellulites, impetigo bullosa, or wound infection) or can gain access to the blood and cause
bacteremia.

Table 3.1: Primary and secondary infections caused by S. aureus
Primary symptoms
Furuncle or carbuncle
Impetigo bullosa
Surgical wound infection
Pyomyositis
Botryomycosis
Acute or right-sided endocarditis
Epidural abscess
Toxic shock syndrome
Scalded skin syndrome

3.1.4

Secondary symptoms
Cellulites
Hospital-acquired bacteremia
Hematogenous osteomyelitis
Septic arthritis
Brain abscess
Hospital-acquired pneumonia
Emphysema
Septic shock
Food-borne gastroenteritis

Multi-Drug-Resistance in S. aureus:
MRSA are not only resistant to methicillin, but maybe resistant to as many as 20

different antimicrobial compounds, including various biocides, representing most of the
available drug classes (Table 3.2). According to most surveys (Archer, 1991, Truckiss,
1991), 50% of MRSA are also resistant to macrolides, lincosamides, fluoroquinolones,
and amino glycosides. The threat posed by such antibiotic-resistant pathogens to patient
health and to the community in general has initiated considerable research into the nature
of the genes encoding antibiotic resistance and the mechanisms by which these genes
spread and evolve in bacterial populations.
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Goldenseal leaf extract exhibited effective antimicrobial activity on the NorA
pump carrying strain of S. aureus and CmeABC pump carrying strain of C. jejuni. For the
further analysis, three more different MDR pumps isolated from S. aureus were chosen
and a brief description of each is given below:
NorA Efflux Pump:
The NorA MDR efflux extrudes various structurally distinct compounds such as:
berberine, ciprofloxacin and ethidium bromide. It is mainly responsible for
fluoroquinolone resistance in S. aureus (Nikaido, 2009). The gene for this pump, norA is
present on the chromosome (Yoshida, 1990) and the MDR strains over express the gene
norA in comparison to the wild type strain. NorA belongs to the major facilitator super
family (MFS) of pumps and has 12 transmembrane segments (Paulsen, 1996). The NorA
show structural homology to the Bacillus subtilis Bmr and Blt pumps and NorA mediated
drug transport like that of Bmr is reserpine sensitive (Kaatz, 1993).
MepA Efflux Pump:
MepA is the first S. aureus MATE family MDR transporter to be identified and is
capable of transporting several clinically relevant biocides and antimicrobial agents. It is
repressed by the product of mepR, which is present on the same gene cluster as mepA in,
the mepRAB cluster (Kaatz, 2006). The gene cluster is present on the chromosome, while
in the wild type only the mepR is seen, in the over expressers, the whole mepRAB cluster
is seen. Like the NorA pump the MepA MATE pump is sensitive to reserpine.
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Table 3.2: Examples of Antimicrobial Resistance Determinants in S. aureus (Slade,
2006)
Antimicrobial agent
Biocides
Bleomycin
Chloramphenicol
Chloramphenicol,
lincosamides, linezolid
Fluoroquinolones
Fluoroquinolones
Fluoroquinolone
Fusidic acid
Fusidic acid
Gentamicin, kanamycin

Resistance determinant
qacA, B, C
ble
cat
cfr

Mechanism of resistance
Multidrug efflux pump (MFS)
Bleomycin binding protein
Chloramphenicol acetyltransferase
23S rRNA methyltransferase

grlA/B
gyrA/B
norA
fusA
fusB
aacA-aphD

Linezolid
Methicillin, oxacillin
MLS group
MLS group
MLS group
Streptogramin A
Streptogramin A
PStreptogramin B
Mupirocin
Mupirocin
Neomycin, kanamycin
Neomycin, kanamycin
Penicillin
Penicillin
Rifampicin
Spectinomycin
Streptomycin
Streptomycin
Streptothricin
Tetracycline
Tetracycline
Tetracycline, minocycline
Tigecycline
Trimethoprim
Trimethoprim
Vancomycin, teicoplanin

23S rRNA genes
mecA
erm(A)
erm(B)
erm(C)
vga(A)(B)
vat(A)(B)
vgb(A)
ileS
ileS-2
aphA-3
aadD
blaZ
mecA
rpoB
spc
str
aadE
sat4
tetA(K)
tetA(L)
tetA(M)
mepA
dfrA
dfrB
vanHAXYZ

DNA topoisomerase IV
DNA gyrase
Multidrug efflux pump (MFS)
EF-G (elongation factor)
Fusidic acid detoxification
6′-aminoglycoside N-acetyltransferase/2″aminoglycoside phosphotransferase
23S rRNA
PBP2a (low-affinity PBP)
rRNA adenine N-6-methyltransferase
rRNA adenine N-6-methyltransferase
rRNA adenine N-6-methyltransferase
MLS efflux pump (ABC)
Virginiamycin A acetyltransferase
Streptogramin B lyase
Isoleucyl tRNA synthetase
Insensitive isoleucyl tRNA synthetase
Aminoglycoside phosphotransferase
Aminoglycoside adenyltransferase
Class A b-lactamase
PBP2a (low-affinity PBP)
RNA polymerase b-subunit
Spectinomycin adenyltransferase
Streptomycin adenyltransferase
Streptomycin adenylyltransferase
Streptothricin acetyltransferase
Tetracycline efflux pump (MFS)
Tetracycline efflux pump (MFS)
Ribosomal protection protein
Multidrug efflux pump (MATE)
Insensitive dihydrofolate reductase
Insensitive dihydrofolate reductase
Glycopeptide resistance
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MsrA Efflux Pump:
The MsrA pump extrudes macrolides and has been isolated from various strains
of S. aureus. It belongs to the RND MDR pump family. No known EPIs of the MsrA
have been reported until recently, diterpine totaral was recently shown to have inhibitory
activity against this pump (Kaatz, 2007).
3.1.5

Campylobacter jejuni
Campylobacter jejuni is one of the leading causes of gastroenteritis in humans in

USA and worldwide (Wesley, 2000). Instances of infections due to Campylobacter date
back to 1886, when Escherich observed campylobacters in the stools of children with
diarrhea (Kist, 1985). These were determined to be the cause of diarrhea in 1956 but were
thought to be Vibrio (King, 1957). The genus Campylobacter was proposed in 1973
(Vernon, 1973) and by 1980s Campylobacter was identified to be the leading cause of
bacterial gastroenteritis by worldwide (Allos, 2001). C. jejuni is a microaerophilic Gram
negative, oxidase positive curved rod exhibiting corkscrew motility. C. jejuni is a thermo
tolerant bacterium, with the ability to grow at temperatures between 41°C-43°C but are
unable to grow below 30°C due to absence of cold-shock proteins (Hernandez, 1991). Its
cephalothin resistance is applied to isolate it from cephalothin-sensitive noncampylobacter diarrhea-causing bacteria.
3.1.6

Pathogenesis of C. jejuni
The infectious disease caused by Campylobacter is called campylobacteriosis.

The gastroenteritis symptoms of C. jejuni are usually indistinguishable from other similar
pathogens like Shigella, Yersinia, etc. These include more commonly diarrhea, fever and
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abdominal cramps and less frequently becteremia, septic arthritis and other extra
intestinal symptoms (Sorvillo, 1991). The incidence of campylobacteriosis is more in
HIV infected patients and common complications in the patients include recurrent
infections and infections due to antibiotic resistant strains (Perlman D J, 1988).
Campylobacteriosis leads to a much more serious disorder called the Guillain-Barré
syndrome in about 40% of patients (Allos, 1997). Guillain-Barré syndrome is an acute
demyelinating disorder of the central nervous system. Only certain serotypes of C. jejuni
are known to increase the chances of contracting this disorder.
Poultry is considered as the main reservoir for C. jejuni, though other agents such
as water, raw milk and direct transmission from pets has also been reported (Butzler,
2004). Campylobacteriosis is majorly self limiting, but antibiotic resistant strains are
more prominent in immune-compromised individuals such as HIV patients or in
persistent infections. In such cases the usual antibiotics preferred were fluoroquinolones
and macrolides. C. jejuni is carried in the intestine of many wild and domestic animals,
particularly avian species, where the intestine is colonized resulting in healthy animals as
carriers. Wildlife has long been considered an infectious reservoir for campylobacters
because of their close association with and contaminated surface waters (Levin, 2007).
3.1.7

Antibiotic Resistance in C. jejuni:
It is a concern that due to use of antibiotics in food animals as therapeutic agents

or growth promoters and since C. jejuni can be passed from animals to humans, antibiotic
resistant C. jejuni might arise (Angulo, 2004). A significant rise in macrolide and
fluoroquinolone resistance has been reported in human isolates of C. jejuni since the
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1990’s (Engberg, 2001). This could have been accelerated due to widespread use of these
antibiotics. Fortunately the prevalence of macrolide resistance in C. jejuni human isolates
has remained low (12%) (Gibreel, 2006) while the prevalence of fluoroquinolone
resistance has increased very high (90%) (Prats, 2000).
3.1.8

Multi-Drug-Resistance (MDR) in C. jejuni:
In 2002, the RND efflux pump CmeABC in C. jejuni was described. This pump

confers resistance to several antimicrobials including fluoroquinolones, erythromycin,
tetracycline, chloramphenicol and ampicillin, as well as detergents and dyes (Jun Lin,
2002). To date, a number of studies have defined a contributory role of the CmeABC
efflux system to acquired MDR (Pumbwe, 2004). CmeABC consists of three components
as is characteristic of RND pumps, a periplasmic fusion protein (CmeA), an inner
membrane transporter (CmeB) and an outer membrane channel protein (CmeC). The
three components are encoded by a single polycistronic operon (cmeABC). An insertion
mutation in the cmeB increases the susceptibility of the resistant strains to some of the
antimicrobials, which indicates the presence of other efflux pumps (Jun Lin, 2002).
It has been shown that the CmeABC pump acts synergistically with gyrA
mutations to confer fluoroquinolone resistance (Luo, 2003). In contrast to other bacteria
where over expression of efflux pump activity is largely associated with acquired
fluoroquinolone resistance (Kaatz, 2005), fluoroquinolone resistance in C. jejuni does not
appear to require over expression of efflux pumps and may be mediated by single-step
point mutations in gyrA in the presence of the constitutively expressed CmeABC pump.
The CmeABC pump may also act independently or in synergy with the 23S rRNA
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mutation, which is responsible for macrolide and erythromycin resistance in C. jejuni
(Mamelli, 2005).
Crude 60% grain alcohol goldenseal leaf extract’s activity on some of the MDR
bacterial strains indicates that the concentration of alkaloids, specifically berberine is not
sufficient to such levels of antimicrobial activity. The objective of this study is to analyze
the synergistic effect of goldenseal leaf extract on the inhibition of MDR efflux pumps in
strains of S. aureus and C. jejuni.

3.2
3.2.1

Materials and Methods

Bacterial Strains:
The list bacterial of strains used in this study are listed in Table 3.3 along with the

MDR pump expressed in them and the associated MDR pump family. S. aureus strains
SA1199 (norA wild type), SA1199B (norA over expresser), RN4220 (msrA) and
SAK2068 (mepA) and Escherichia coli strains DH10B and DH10B/pK21 (wild type
DH10B with norA carrying plasmid pK21) were kindly provided by Dr. Glenn Kaatz
(Wayne State University School of Medicine, Detroit, MI). S. aureus 25923 and L.
acidophilus 53544 were obtained from ATCC, Richmond VA. All the strains were
maintained in Mueller Hinton II (MH II) (BD-Difco) medium at 35°C under aerobic
conditions.
C. jejuni 81-176 (cmeABC) is a human isolate provided by Dr. Jun Lin of the
Department of Animal Science at the University of Tennessee. These isolates were
routinely grown in Mueller-Hinton II (MH II) broth (BD-Difco) or agar at 42°C under
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microaerophilic conditions generated using the Anoxomat system (Mart Microbiology) in
enclosed jars.
Table 3.3: List of bacterial Strains
Strain
S. aureus SA1199
S. aureus SA1199B
S. aureus SAK2068
S. aureus RN 4220
S. aureus ATCC 25023
E. coli DH10B
E. coli DH10B/pK21
C. jejuni 81-176

3.2.2

Description
Wild type NorA
Over expresser NorA
MepA
MsrA
Plasmid containing norA gene
CmeABC

MDR pump family
MFS
MFS
MATE
RND
MFS
RND

Antimicrobial Assay:
The minimum inhibitory concentrations (MICs) of different antimicrobials,

goldenseal leaf extract and berberine sulfate were determined by using the microbroth
assay as described by the Clinical and Laboratory Standards Institute (CLSI) for the S.
aureus. The antimicrobial is added in serial two-fold dilutions in triplicates to round
bottom 96 well plate and each well is seeded with 105cell/ml in MH II broth (final
volume in each well is 200µL). The plates are incubated aerobically at 35°C for 18-24hrs
and observed for visible growth. MIC is defined as the lowest concentration of the
antimicrobial with no visible growth. The assays were performed twice in triplicates. All
the chemicals and antimicrobials were obtained from Sigma-Aldrich. Goldenseal leaf
extract was provided by Sleepy Hollow farm, GA.
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The minimum bactericidal concentration (MBC) is determined by taking the
100µL from the wells that show no visible growth (≥ MIC) in the microbroth assay and
resuspending in fresh liquid and on solid MH II media. The agar and broth is incubated
aerobically at 35°C for 18-24hrs and observed for growth. MBC is defined as the lowest
concentration which yielded no growth. All assays were performed twice in triplicates.
For C. jejuni 81-176 the MICs were determined using the standard 96 well
microtiter broth dilution method in MH II broth with an inoculum of 106cell/mL.
Microtiter plates were incubated for 48 hrs under microaerophilic conditions at 42°C and
observed for visual growth. The assays were performed twice in triplicates.
3.2.3

Synergistic assay of goldenseal leaf extract:
The pump inhibitory activity of goldenseal leaf extract on the S. aureus strains

was performed by a slight modification of the microbroth assay. Sub-lethal doses of the
antimicrobial being tested and sub-lethal doses of goldenseal leaf extract are added
together in the wells of the 96 well plates. The plates were then seeded with 105cell/mL
in MH II broth (final volume 200µL/well). The plates were incubated aerobically at 35°C
and observed for visible growth. The decrease in MIC is then measured in fold-decrease.
Reserpine, a known MDR pump inhibitor, was used as a standard for MDR pump
inhibitory activity. For the C. jejuni strains the plates were seeded with 106cell/mL in MH
II broth. The plates were incubated for 48 hrs under microaerophilic conditions at 42°C
and observed for visible growth.
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3.2.4

Agar well-diffusion assay
To demonstrate synergy between the goldenseal leaf extract and antimicrobials on

the bacteria, a slightly modified technique of agar-well diffusion assay as described
earlier (Schillingeur and Lucke,F, 1989). MH II agar plates were overlaid with soft agar
seeded with 105cell/mL of the indicator bacteria (SA1199B). Wells of 1mm in diameter
were then punched in the agar and the antimicrobial agent (goldenseal leaf extract or
ciprofloxacin) added to them. The diameter of the zone of inhibition (ZOI) was
measured. Synergy was demonstrated by placing the wells of ciprofloxacin and
goldenseal leaf extract with a measured distance from the edge of ZOI of ciprofloxacin to
the Zone of goldenseal leaf extract. A disfiguration of ZOI would indicate the
synergy/antagonism between the two agents.
3.2.5

Quantitative Real-Time RT-PCR:

RNA extraction:
The bacteria were grown overnight in MH II broth with or without sub-lethal
doses of the EPIs (Reserpine or goldenseal leaf extract). Total RNA was then extracted
from the bacteria using the 1-2-3 RNA extraction kit from Idaho Technologies according
to the manufacturer’s protocols. 100µL of the cell culture was added to the bead tubes
and the carrier RNA (RNA module) and vortexed for 5min on a Vortex Genie to lyse the
bacteria. 450µL of the binding buffer was added to the lysate. The lysate was transferred
avoiding the beads to a spin filter and centrifuged. The spin filter was washed twice with
wash buffer and RNA was eluted in 50µL of the elution buffer.
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The concentration of total RNA was determined by spectrophotometer readings at
260nm. The purity of the RNA was confirmed by doing a ratio of absorbance at 260nm
and 280nm and running a formaldehyde agarose gel electrophoresis.
Real-Time RT-PCR:
The Bio-Rad MiniOpticon Real-Time PCR Detection system was used to amplify
cDNA following reverse transcription of the isolated total RNA so that differences in
gene expression levels could be easily measured. Use of the Bio-Rad iScript™ One-Step
RT-PCR Kit with SYBR Green allowed for reverse transcription and PCR to be carried
out in one tube with fluorescence of SYBR green measured at the end of each cycle. For
one-step RT-PCR, 25µL reaction volumes containing the followings per tube were used:
12.5µL of 2x SYBR green master mixes, 0.5µL of 10µM forward primer, 0.5µL of 10µM
reverse primer, 0.5µL of reverse transcriptase, 25ng RNA, and RNAase free water to
bring the reaction volume to 25µL. Triplicate samples were run in duplicate under the
following conditions: cDNA synthesis at 50°C for 10 minutes, RT inactivation and initial
denaturation at 95°C for 5 minutes, denaturation for 10 seconds at 95°C and annealing
(data collection step) for 30 seconds at 53.8°C for 35-45 cycles. The primers used in the
gene expression assay are listed in Table 3.4. The purity of the amplicon was determined
by doing a melt curve analysis.
Analysis of the data generated by the RT-PCR was done by the comparative Ct
method. The Ct values of both the control and the samples of interest were normalized to
an appropriate endogenous housekeeping gene (16S rRNA). The threshold cycle, Ct, is
defined as the cycle at which fluorescence crosses into the exponential phase from the
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initial linear phase. The standard curve method was not considered as the amounts of
RNA added to the reaction mixture were known.

Table 3.4: List of primers for different strains of S. aureus used in Real time RT-PCR
Strain

Gene

S. aureus
housekeeping
SA1199,
SA1199B
SAK2068
RN4220
C. jejuni
housekeeping
C. jejuni 81176

16S
rRNA
norA

3.2.6

mepA
msrA
16S
rRNA
cmeABC

GenBank
Accession
No.
L37597

Left Primer

Right Primer

tccggaattattgggcgtaa

ccactttcctcttctgcactca

M80252

agaatttatgtttgctatcggt

tttgctttttgatggcttggtg

AY661734
AF167161
Z29326

ggcaaataaaggccgtatga
agctgtgcgagatgtacgtg
caacacttttaccgggtgct

cagtcgcttgaagcatacca
atgcttggtcctccctttct
gccattttgcaatcctttgt

AF466820

gagtgagggagaggcagatg

gtttagggcgtggactacca

Ethidium Bromide Uptake:
Uptake of EtBr by the bacteria was achieved by growing the bacteria overnight in

MH II broth. Bacteria were harvested at an OD660 of 0.7 to 0.8, washed in ice-cold MH II,
and then resuspended in MH II to a final OD660 of 0.4. The suspension was warmed to
37°C, and ethidium bromide (final concentration, 20µg/mL) was added. The suspension
was maintained at 37°C with agitation, and the fluorescence of aliquots was determined
at frequent intervals (excitation wavelength, 530nm; emission wavelength, 600 nm). The
effect of reserpine and goldenseal leaf extract on the uptake was measured by adding

39

them to the medium after resuspension. The final concentration of reserpine used was
20µg/mL and that of goldenseal leaf extract was 500µg/mL.
3.2.7

Ethidium Bromide Efflux:
Ethidium bromide efflux studies were performed as described earlier with some

differences (Kaatz, 2006). For ethidium bromide efflux, bacteria were grown overnight in
MH II and diluted into the same medium as used for overnight growth, and at an OD660 of
0.7 to 0.8. Ethidium bromide loading of bacteria was accomplished by the addition of
ethidium bromide and reserpine (final concentrations of both being 20µg/mL). After 20
min of incubation at room temperature, the OD660 was adjusted to 0.4 using fresh MH II
containing ethidium bromide and reserpine or goldenseal leaf extract. Bacteria in 1 ml of
this dilution were pelleted and then resuspended in fresh MH II without reserpine or
ethidium bromide. Efflux of ethidium bromide was monitored by measuring the
fluorescence of the suspension continuously (excitation and emission wavelengths, 530
and 600 nm, respectively). The effect of reserpine (20µg/mL) and goldenseal leaf extract
(500µg/mL) was determined on the efflux of ethidium bromide.
3.2.8

Statistical Analysis:
Numbers expressed as mean ± standard deviation were analyzed by Student’s T

test. Values were considered significantly different when p values were less than 0.05.
Notations were also made when p<0.01.
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3.3
3.3.1

Results

Antimicrobial Assay:
The MICs of different antimicrobials on the bacterial strains are given in Table

3.5 and 3.6. Table 3.5 is the results of the antimicrobial activity of ciprofloxacin,
goldenseal leaf extract, berberine sulfate and reserpine against the NorA strains. The MIC
of ciprofloxacin against the over expresser NorA strain SA1199B was 32-fold higher than
that on the wild type, SA1199 while on DH10B/pK21, it was 3-fold higher than the wild
type DH10B.

Table3.5: MIC (µg/mL) of antimicrobials on the NorA pump expressing strains
Antimicrobial
Ciprofloxacin
Goldenseal Leaf
Extract
Berberine sulfate
Reserpine

SA1199 SA1199B DH10B DH10B/pK21
0.25
8
0.02
0.06
1000
1000
1000
1000
125
> 250

>250
250

250
>250

>250
250

The MICs of different antimicrobials on other indicator bacteria are given in
Table 3.6. The MIC of goldenseal leaf extracts on all the S. aureus strains was
comparable, but it exhibited a much lower MIC on the C. jejuni strain. Similarly the MIC
of berberine on all the MDR S. aureus was high compared to that on C. jejuni. Reserpine
showed a high MIC on all the S. aureus, E.coli and C. jejuni strains suggesting that
reserpine has limited antimicrobial property.
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Table 3.6: MICs (µg/mL) of different antimicrobials on the MDR strains
Antimicrobial
Ciprofloxacin
Tetracycline
Erythromycin
Goldenseal Leaf
Extract
Berberine sulfate
Reserpine
3.3.2

SA1199B
8
0.25
0.25
1000

SAK2068
4
1
0.5
500

RN4220
0.25
0.25
64
1000

C. jejuni 81-176
0.313
50
0.078
62.5

125
> 250

250
>250

250
>250

8
>100

Synergy Studies:

3.3.2.1 Microbroth assay:

The synergistic activity of goldenseal and reserpine with other antimicrobials was
evaluated against all the MDR strains. The results for synergy between ciprofloxacin and
goldenseal leaf extract on the NorA strains are shown in Table 3.7. The sub lethal doses
of goldenseal leaf extract evaluated were 500, 250 and 125µg/mL. There was no
reduction in MIC of ciprofloxacin on the wild type NorA S. aureus strain SA1199. The
MIC of ciprofloxacin on the NorA over expresser, SA1199B was reduced to 1µg/mL,
which was an 8-fold reduction, when a sub lethal dose of 500µg/mL of goldenseal leaf
extract was used. There was a 4-fold and 2-fold reduction in the MIC of ciprofloxacin
observed for sub lethal doses 250µg/mL and 125µg/mL respectively. Different
concentrations of reserpine were also assayed as controls. An 8-fold decrease in
ciprofloxacin was observed when 20µg/mL of reserpine was used. A 4-fold and 2-fold
decrease in ciprofloxacin was observed for 10µg/mL and 5µg/mL of reserpine
respectively.
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In the case of the E. coli strains the sub lethal doses of goldenseal leaf extract
used were 500, 250 and 125µg/mL. There was a decrease in MIC of ciprofloxacin on E.
coli DH10B/pK21 by 8-fold (0.0075µg/mL) observed for 500µg/mL of goldenseal leaf
extract. A 4-fold and 2-fold decrease in MIC of ciprofloxacin seen with 250µg/mL and
125µg/mL of goldenseal leaf extract was observed, respectively. No reduction was
observed in the case of DH10B with goldenseal leaf extract. Reserpine at a concentration
of 20µg/mL exerted a decrease of MIC of ciprofloxacin by 16-fold on the E. coli
DH10B/pK21 and an 8 fold decrease on the DH10B strain with 20µg/mL concentration.
An 8-fold and 4-fold reduction of MIC of ciprofloxacin on E. coli DH10B/pK21 and 4fold and 2-fold decrease of MIC of ciprofloxacin on DH10B was observed with 10µg/ml
and 5µg/mL of reserpine respectively.

Table 3.7: MDR pump inhibitory activity of goldenseal leaf extract on NorA strains. All
the concentrations are in µg/mL and degree of decrease in MIC is in
parenthesis
Antimicrobial
Ciprofloxacin
Goldenseal
Ciprofloxacin +
Goldenseal
500µg/mL
250µg/mL
125µg/mL
Ciprofloxacin +
Reserpine
20µg/mL
10µg/mL
5µg/mL

SA1199
SA1199B
DH10B
0.25µg/mL 8 µg/mL
0.02µg/mL
1000µg/mL 1000µg/mL 1000µg/mL

DH10B/pK21
0.06µg/mL
1000µg/mL

No change

1µg/mL (8) No change
2µg/mL (4)
4µg/mL (2)

0.0075µg/mL (8)
0.015µg/mL (4)
0.03µg/mL (2)

No change

1µg/mL (8) 0.0075µg/mL (8) 0.0037µg/mL(16)
2µg/mL (4) 0.015µg/mL (4) 0.0075 µg/mL (8)
4µg/mL (2) 0.03µg/mL (2)
0.015µg/mL (4)
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The synergy between other antimicrobials and goldenseal leaf extract are shown
in Table 3.8. The sub lethal concentration of goldenseal leaf extract used for the synergy
assay were 250µg/mL and 500µg/mL for SAK2068 and RN4220 and those of reserpine
were 20µg/mL for both strains. The assay was also done on the ATCC 25923strain as a
control.
Goldenseal leaf extract exhibited a decrease in the MIC of ciprofloxacin from 4 to
1µg/mL, a 4-fold decrease on the SAK2068, the MATE pump strain. There was also a 4fold reduction from 1 to 0.25µg/mL of tetracycline and 2-fold reductions from 0.5 to
0.25µg/mL of erythromycin in synergy with goldenseal leaf extract on the SAK2068. A
reduction of 2-fold in the MIC of ciprofloxacin and erythromycin was observed in the
RN4220, the RND pump strain with goldenseal leaf extract. No change was observed in
the MIC of tetracycline on RN4220 with goldenseal leaf extract. Goldenseal leaf extract
showed a 2-fold reduction in the MIC of both, tetracycline and erythromycin on
SA1199B, the MFS pump strain. The synergy effects of goldenseal leaf extract were
comparable to those of reserpine on all the strains at a concentration of 20µg/mL.
The sub lethal dose of goldenseal leaf extract for synergy studies of C. jejuni 81176 used was 31.25µg/mL. The MIC of ciprofloxacin against C. jejuni 81-176 was
lowered by 16-fold from 0.313µg/mL to 0.004µg/mL. When the sub lethal dose of
goldenseal leaf extract was lowered to 16µg/mL, an 8-fold decrease in MIC of
ciprofloxacin was observed. Reserpine at a concentration of 20µg/mL showed a 2-fold
decrease in MIC of ciprofloxacin against C. jejuni 81-176. Synergy of goldenseal leaf
extract with tetracycline on C. jejuni 81-176 was not evaluated as the resistance of this
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strain towards tetracycline id due to a different pump and not conferred by CmeABC (Jun
Lin 2002).

Table 3.8: MDR pump inhibitory activity of goldenseal leaf extract on MDR S. aureus
strains. All the concentrations are in µg/mL and degree of decrease in MIC is
in parenthesis. The sub lethal dose of goldenseal leaf extract for each stain is
half its MIC against the strain given in parenthesis after the strain description.
The concentration of reserpine used was 20µg/mL
Antimicrobial SA1199B
(500µg/mL)
Goldenseal
1000µg/mL
Ciprofloxacin 8µg/mL
+Goldenseal
1(8 fold)
+Reserpine
1(8 fold)
Tetracycline
0.25µg/mL
+Goldenseal
0.125(2 fold)
+Reserpine
0.125(2 fold)
Erythromycin 0.25µg/mL
+Goldenseal
0.125(2 fold)
+Reserpine
0.125(2 fold)

SAK2068
(250µg/mL)
500µg/mL
4µg/mL
1(4 fold)
0.5(8 fold)
1µg/mL
0.25(4 fold)
0.5(2 fold)
0.5µg/mL
0.25(2 fold)
0.5(none)

RN4220
(500µg/mL)
1000µg/mL
0.25µg/mL
0.125(2 fold)
0.125(2 fold)
0.25µg/mL
0.25(none)
0.125(2 fold)
64µg/mL
32(2 fold)
64(none)

SA25923
(500µg/mL)
1000µg/mL
0.125µg/mL
0.062(2 fold)
0.062(2 fold)
0.25µg/mL
0.25(none)
0.25(none)
0.125µg/mL
0.125(none)
0.125(none)

C. jejuni 81-176
(31.25µg/mL)
62.5µg/mL
0.313µg/mL
0.0039(16 fold)
0.1565(2 fold)
0.078µg/mL
0.0395(2 fold)
0.078(none)

3.3.2.2 Agar Diffusion assay:

The agar diffusion assay was performed on the NorA over expresser S. aureus
strain SA1199B to demonstrate the synergy between goldenseal leaf extract and
ciprofloxacin. The zone of inhibition of different concentrations of ciprofloxacin and
goldenseal leaf extract was initially determined. The well containing the ciprofloxacin
(5µg) was then surrounded by wells with different concentrations of goldenseal leaf
extract (130µg, 260µg, 390µg and 520µg). The distance between the edges of ZOIs is
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varied in different plates (Figure 3.2). The deformation in the ZOI of ciprofloxacin
towards the ZOI of leaf extract indicates that there may be synergy between goldenseal
leaf extract and ciprofloxacin.
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B

B

C
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D
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Figures 3.2: Agar diffusion assay of SA1199B, dist bet ZOI (i) 3mm, (ii) 5mm, iii)7.5mm
and (iv)10mm. Wells A-D represent increasing concentrations of leaf
surrounding the center well of ciprofloxacin

3.3.3

Quantitative Real-Time RT-PCR:

RNA extraction:
After extraction, only the RNA samples that showed a 260/280 ratios falling
between 1.9-2.1 were selected for the polymerization reaction. A formaldehyde gel
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electrophoresis of the samples showed a double band of RNA without any contaminants
as is characteristic of the RNA.
Real-Time RT-PCR:
The comparative Ct method was employed to analyze the RT-PCR results. Ct
refers to the threshold cycle where the fluorescence of the reporter crosses from linear
into the exponential range.

∆∆Ct = ∆Ct control – ∆Ct unknown sample

∆Ct control = Ct housekeeping – Ct control
Ratio of the sample to the control = 2-∆∆Ct

The 2-∆∆Ct values were interpreted as follows: for values less than 1, the treatment
caused the sample to have a 2-∆∆Ct value lower than the reference (housekeeping)
indicating a decrease in MDR pump gene expression; values equal to 1 mean that the
sample had the same 2-∆∆Ct as the reference and thus no change in gene expression
between treatment and non-treatment; and values of greater than 1 indicate the treatment
caused the sample to have a greater 2-∆∆Ct value than the reference, meaning an increase
in MDR pump gene expression compared to untreated bacteria.
The 2-∆∆Ct of the NorA strains SA1199 and SA1199B both treated and untreated
with goldenseal leaf extract or reserpine are given in Table 3.9. The 2-∆∆Ct values of the
wild type NorA SA1199 remained unchanged for both the treated and untreated samples.
The 2-∆∆Ct of SA1199B bacteria treated with 20µg/mL reserpine was less than 1 and
significantly different from those of the untreated bacteria (p < 0.05) indicating a gene
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repression. At lower doses reserpine exerted an increase in the gene expression with
significantly different from the untreated bacteria. The 2-∆∆Ct of SA1199B bacteria treated
with goldenseal leaf extract are less than one for all the three doses, 500µg/mL,
250µg/mL and 125µg/mL indicating a decrease in the norA gene due to treatment with
goldenseal leaf extract. In comparison to the untreated bacteria and bacteria treated with
reserpine, the gene repression by goldenseal was highly significant (p < 0.01).There was
a general increase in the 2-∆∆Ct values as the dose of the goldenseal decreased.

Table 3.9: 2-∆∆Ct of S. aureus NorA strains
EPI
Reserpine
20µg/mL
10µg/mL
5µg/mL
Goldenseal leaf extract
500µg/mL
250µg/mL
125µg/mL
n=6

2-∆∆Ct SA1199 2-∆∆Ct SA1199B
1
1
1

0.82
1.04
1.30

1
1
1

0.23
0.34
0.53

The norA strains SA1199 and SA1199B were also treated with sub lethal doses of
ciprofloxacin and berberine sulfate and subjected to real-time RT-PCR. No difference in
the 2-∆∆Ct of treated and untreated samples was observed.
The real-time RT-PCR results of other MDR strains are listed in Table 3.10. The
concentration of goldenseal leaf extract used for SAK2068 was 250µg/mL, for RN4220
was 500µg/mL, and for C. jejuni 81-176 was 31.25µg/mL. The concentration of reserpine
used was 20µg/mL. The 2-∆∆Ct of the mepA of the MATE MDR strain, SAK2068 treated
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goldenseal leaf extract* or reserpine^ were both less than 1 showing significant decrease
in gene expression (*p < 0.01, ^p < 0.5). But the 2-∆∆Ct of SAK2068 treated with
goldenseal was much lower than that of the SAK2068 treated with reserpine (p < 0.05).
The results suggest that the mepA gene expression was reduced more with goldenseal leaf
extract compared to reserpine. Similar results were observed in RN4220, the 2-∆∆Ct of
RN4220 treated with goldenseal leaf extract was significantly lower than that of reserpine
(p < 0.05), indicating a higher repression of msrA with goldenseal leaf extract compared
to reserpine. The 2-∆∆Ct of bacteria treated with reserpine remained 1 indicating no change
in gene expression while those treated with goldenseal leaf extract showed a 2-∆∆Ct of less
than 1 indicating a gene repression exerted by goldenseal leaf extract. The level of gene
repression by goldenseal leaf extract is shown in Figure 3.3.
The 2-∆∆Ct of C. jejuni 81-176 treated with goldenseal leaf extract was
significantly lower than that of the untreated bacteria

(p < 0.01) while the 2-∆∆Ct of

reserpine was similar to those of the untreated bacteria.
Table 3.10: 2-∆∆Ct values of the MDR bacteria
EPI
Leaf extract
Reserpine
n=6

SA1199B
(MFS)
0.23
0.82

SAK2068
(MATE)
0.19
0.71
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RN4220
(RND)
0.27
0.58

C. jejuni 81-176
(RND)
0.184
1

The real-time RT-PCR was also done on RNA extracted from SAK2068, RN4220
and C. jejuni 81-176 bacteria treated with sub lethal doses of ciprofloxacin or berberine
sulfate. No change was observed.

Figure 3.3: Effect of goldenseal on the gene expression of MDR pump genes
n=6, *p<0.01, ^p<0.05

3.3.4

Ethidium Bromide Uptake:
The Ethidium Bromide (EtBr) uptake of bacteria without any EPI is shown in the

chart in Figure 3.4: The wild type NorA strain showed a steady increase in fluorescence
indicating accumulation of EtBr in the bacteria, which normalized after a time. All the
other MDR bacteria showed an increase in initial EtBr uptake and after an interval there
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is a decrease in fluorescence. This might indicate the efflux of EtBr by the the MDR
efflux pumps.

50
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SA1199
SA1199B
SAK2068
RN4220
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EtBr uptake by bacteria

0

20
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Time in min
Figure 3.4: Ethidium bromide uptake of S. aureus strains
n=6
The effect of reserpine and goldenseal leaf extract on the bacteria is shown in the
charts in Figures 3.5 and 3.6. Compared to the absence of any EPI, reserpine significantly
showed an increase in the fluorescence in all the MDR bacteria (p <0.05) which after a
time still increases but at a very slow rate. This was true in the case of SA1199 wild type
strains also, which also shows a sharp accumulation initially and then a gradual slow
increase in fluorescence.
The effect of goldenseal leaf extract is shown in the chart in Figure 3.6.
Goldenseal leaf extract showed an opposite effect of reserpine. The goldenseal leaf
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extract did not show any effect on the EtBr uptake in the wild type SA1199, which
showed a similar line as in with just the SA1199 bacteria without EPIs. Similar was the
case with the MDR bacterial strains on which the goldenseal leaf extract did not show an
increase in the EtBr accumulation. One deviation observed was the sudden sharp increase
and decrease in fluorescence in the case of the MsrA pump RN4220.
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SA1199B
SAK2068
RN4220

50

100

Reserpine

0

Fluorescence in arbitrary units

200

Effect of Reserpine on EtBr uptake by bacteria

0

20

40

60

Time in min
Figure 3.5: Effect of reserpine on EtBr uptake of S. aureus strains, reserpine was added
10 min after EtBr exposure. n=6
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Effect of Goldenseal on EtBr uptake by bacteria
Fluorescence in arbitrary units
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SA1199B
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0
0

20

40

60

Time in Min
Figure 3.6: Effect of goldenseal leaf extract on EtBr uptake of S. aureus strains, extract
was added 10 min after exposure to EtBr, n=6

The EtBr uptake by C. jejuni 82-176 bacteria is shown in the chart in Figure 3.7.
The EPIs were added 10 min after the bacteria had been exposed to EtBr. All the three
samples showed a similar increase in fluorescence initially. After 10 min the fluorescence
of the untreated C. jejuni 81-176 stopped increasing and decreased slightly after 50 min
and leveled again. The bacteria to which reserpine was added continued to show a
significant increase (p < 0.05) in comparison to the bacteria without EPIs in fluorescence
before falling slightly at 50 min. The bacteria treated with goldenseal leaf extract
however showed a significant decrease in the fluorescence right after it was added and
continued decreasing before leveling off at 40 min in comparison to the bacteria without
any EPI.
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Figure 3.7: Effect of goldenseal leaf extract and reserpine on the EtBr uptake of C. jejuni
81-176 bacteria n=6

3.3.5

Ethidium Bromide efflux:
For the EtBr efflux studies the bacteria had to be first primed with an EPI such as

reserpine which would enable the bacteria to accumulate EtBr without effluxing it out.
These bacteria were then washed and resuspended in fresh medium without any EPI. The
efflux of EtBr from the bacteria was then observed along with the effect of reserpine
(20µg/mL) and goldenseal leaf extract (500µg/mL) on the efflux of ethidium bromide
from the bacteria.
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Ethidium bromide efflux in S. aureus strains
Fluorescence in arbitrary units
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Figure 3.8: Ebro efflux of strains SA1199 and SA1199B in the presence and absence of
MDR pump inhibitors n=6

Proserpine inhibited the efflux of Ebro as indicated by no decrease in fluorescence
in the SA1199B (Figure 3.8). While goldenseal leaf extract did not inhibit the Ebro
efflux, as the fluorescence decreased gradually with time. There was no effect of
reserpine or goldenseal leaf extract on the efflux of EtBr from the wild type SA1199
bacteria.
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3.4

Discussion

Goldenseal leaf extract, though limited in its antimicrobial activity, potentates the
activity of other antimicrobials. There was a higher EPI activity of goldenseal leaf extract
observed on the SA1199B (NorA- MFS pump super family) and the SAK2068 (MepAMATE pump super family) with more than 4-fold decrease in the MIC of ciprofloxacin
seen. Limited activity was seen against the MsrA pump (RND pump super family)
carrying RN4220 with only a 2-fold decrease in the MIC of macrolide tested
(erythromycin).
Goldenseal leaf extract increases the susceptibility of the CmeABC pump
carrying strain of C. jejuni: 81-176 towards ciprofloxacin and erythromycin, by
repressing the gene encoding the pump. Goldenseal leaf extract decreases the MIC of
ciprofloxacin on C. jejuni by 16 folds.
The MDR pump inhibitory activity of n leaf extract at half MIC was comparable
to that of reserpine. Reserpine has been demonstrated by other groups as an inhibitor of
various MDR pumps including the P-glycoprotein, NorA and MepA (Kaatz, 2006).
Reserpine at the concentrations required to obtain the desired MDR pump inhibitory
activity has been cited to have some side effects such as neurotoxic effects (Moudgal,
2003). The use of goldenseal leaf extract as an EPI could overcome this problem.
Currently many groups are trying to develop EPIs to market as combination therapies.
There are many ways an EPI could act on the MDR pump, three main possibilities
are: reduction in mRNA production (gene repression), interference in the protein pump
function, and/or changing the biochemical structure of the protein pump. The real-time
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RT-PCR and ethidium bromide studies were conducted to analyze this property.
Reserpine reduces NorA mediated EtBr efflux as is demonstrated by the EtBr studies. In
similar assay the goldenseal leaf extract did not show any effect on the EtBr efflux by the
NorA pump.
The mRNA production was determined after incubating the bacteria with sub
lethal doses of goldenseal leaf extract with the MDR bacteria. There was a decrease in the
mdr genes of all the MDR bacteria and C. jejuni. This indicates that there was gene
repression seen when the bacteria were exposed to goldenseal leaf extract. Reserpine
showed an opposite effect on the MDR bacteria. While it reduces the efflux pump
mediated EtBr efflux, there was no significant change in gene expression of the mdr
genes.
The conclusion that can be derived from these observations is that goldenseal
increases the susceptibility of the MDR bacteria to different antimicrobials by decreasing
the mRNA production of the MDR pump genes and does not affect the pump efflux.
There maybe one or more components in the crude goldenseal leaf extract which causes
these effects on the bacteria.
Specifically in the case of the MsrA pump of S. aureus, belonging to the RND
family, until recently no known EPI was available, in 2007, diterpene totaral has been
shown to inhibit the pump (Kaatz, 2007). Goldenseal exhibited an inhibition of this pump
as indicated by the result of synergy studies. Further evaluation of goldenseal leaf extract
on the Gram- negative bacteria C. jejuni that carries the MDR pump CmeABC and MsrA
pump of S. aureus, both of which belong to the RND family determine that goldenseal
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leaf extract has a higher synergistic activity on the CmeABC pump when compared to the
MsrA pump. A more thorough analysis is required to understand the variations in the
effect of goldenseal on pumps belonging to the same family in both Gram positive and
Gram negative bacteria.
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Chapter 4
Separation and Identification of Goldenseal Leaf Extract Constituents

4.1

Introduction

Many active compounds have been previously reported in goldenseal including
alkaloids berberine, hydrastine and canadine (Figure 1.6), secondary metabolites such as
protoanemonin and glycosides, berberastine, meconin, chlorogenic acid, phytosterins,
and resins, albumin, starch, fatty acids, sugars, lignins, and volatile oils. (Van Berkel,
2007). Berberine extracts and salts have been demonstrated to exhibit growth inhibition
of intestinal parasites like Giardia lamblia, Entamoeba histolytica, Trichomonas
vaginalis, (Kaneda, 1990) and Leishmania donovani, (Abidi, 2005) with crude extracts
being more effective than berberine salts (Kong, 2004).
Canadine is known for its sedative and muscle relaxant properties. The third
alkaloid hydrastine is a valuable drug for treatment of skin diseases, both taken internally
and used as topical applications. It is especially useful as a stomachic tonic, and as a
hepatic stimulant in cutaneous infections. It exhibits better activity when used as a topical
application than taken internally (Beckstrom-Sternberg, 1997).
Two new C-methyl flavonoids, 6,8-di-C-methylluteolin 7-methyl ether and 6-Cmethylluteolin 7-methyl ether have been isolated and have

activity against oral

pathogens such as Streptococcus mutans and Fusobacterium nucleatum (Hwang, 2003).
Quinic acid feruloyl esters have also been identified and their activity against
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Mycobacterium tuberculosis was evaluated but showed no significant effect (Gentry,
1999).
The objective of this study was to isolate and identify the constituent(s) in
goldenseal leaf extract which may be associated with the MDR efflux pump inhibitory
activities previously observed.

4.2
4.2.1

Materials and Methods

Goldenseal Leaf Extract Sample
The goldenseal leaf extract was supplied by the Sleepy Hollow Farm and it was a

60% grain alcohol extract with a dry weight of 13mg/mL. A volume of 1mL of the
goldenseal leaf extract was concentrated in using a Speed-Vac and then its final
concentration adjusted to 130mg/mL with 60% grain alcohol.
4.2.2

Bacterial Strains
The S. aureus strains, SA1199B, SAK2068 and RN4220 were used to test for

growth inhibition using thin-layer chromatography (TLC) bioautography were provided
by Dr. Glen Kaatz (Wayne State University School of Medicine, Detroit, MI). The
bacteria were maintained in Mueller Hinton II (MH II) (BD-Difco) medium at 35°C
under aerobic conditions.
4.2.3

Thin Layer Chromatography (TLC)
Preparative thin layer silica gel based glass plates (size 20cm × 20cm) (EMD

Chemicals) incorporated with a fluorescent indicator F254 were used for the separation of
goldenseal leaf extract constituents. Different amounts of the concentrated goldenseal
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leaf extract (1.3mg, 2.6mg and 3.9mg) and berberine sulfate (0.067mg, 0.134mg and
0.201mg) were spotted onto the TLC plates and developed in ascending phase. Four
different solvent systems, i.e. ethyl acetate:methanol (1:1), acetone:ethanol (1:1),
butanol:acetic acid/water (7:1:2) and chloroform:methanol (9:1) were tested to determine
the best solvent system for separation. The TLC chamber was filled with the solvent
mixture, lined with filter paper and allowed to saturate. Spotted TLC plates were then
placed vertically in the chamber and allowed to develop for 15cm. The plates were then
removed and allowed to dry and observed under the fluorescent light immediately. All
the solvents were obtained from OmniSolv EMD Chemicals.
4.2.4

Bioautographic Studies:
To test the antimicrobial activity of various constituents separated on the TLC

plates, TLC bioautographic assay was done as described previously (Choma, 2005) with
slight modifications. The developed TLC plates were dried in the 37°C oven for 4 hours.
The plates were then sprayed with 108cell/mL of the bacteria to be tested, with or without
a sub lethal dose of ciprofloxacin. The plates were then incubated for overnight at 35°C
in a humidified box to prevent the plates from drying. The incubated plates were then
sprayed with 2mg/mL triphenyl tetrazolium chloride (TTC) salt solution and incubated at
37°C for 4hrs and TTC was used to facilitate the detection of the zone of inhibition (ZOI)
of the bacteria.
4.2.5

Sample Preparation For Analysis:
Five concentrated goldenseal samples (13mg each) were spotted onto the TLC

plate and developed in chloroform/methanol (9:1) solvent system. Identical bands among
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the 5 lanes on the developed TLC silica gel were scraped off, resuspended in the same
solvent mixture, and pooled together. Each pooled sample was then vortexed and filtered
through 1.2 followed by 0.2µ PTFE syringe filters.
4.2.6

Gas Chromatography/Mass Spectrometry (GC/MS)
An Agilent 7890 GC system interfaced with an Agilent 5975 mass selective

detector was used (Agilent Technologies, Newark DE). GC/MS analysis of each of the
pooled sample was conducted by injecting 2µL HP-5 MS column (30m x 250µm,
0.25µm). Gas chromatographic operating conditions were as follows: split injection
mode; injector temperature, 250 °C oven temperature, 80°C for 6 min, then programmed
at 5°C/min to 130 °C, and held for 5 min and then 15°C/min to 300°C. The carrier gas
was helium set at a constant flow of 0.4mL/min. The mass spectrometer was turned on at
4min. The mass range scanned was 35-500 amu and the source temperature, 250 °C.
Mass spectral data were processed using the Agilent GC/MSD ChemStation software.
4.2.7

Liquid Chromatography/Mass Spectrometry (LC/MS)
LC/MS analysis was performed on an Agilent 6100 series LC/MS in which a

quadruple mass spectrometer was coupled to an Agilent 1200 HPLC (Agilent
Technologies, Newark DE) that consisted of a G1329A high performance autosampler
(HP-ALS-SL), a G1312A binary pump (BIN-SL), a G1379B vacuum degasser, a
G1316A thermostatted column compartment (TCC-SL) and a G1314B variable
wavelength detector (VWD-SL). The quadruple mass spectrometer was operated with an
atmospheric pressure electrospray ionization (API-ES) source in positive mode. The flow
rate of HPLC was maintained at 1 mL/min through a Kromasil RP C18 column ( column
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size of 150mm × 4.6mm p 5µm particle size, Alltech Associates, Inc. Deerfield, IL). The
mobile phase is an isocratic elution consisted of methanol and water (v/v=87:13)
containing 0.1% H3PO4. Mass spectra were recorded within the m/z range of 100-1000.
The dry gas flow for the MS was 13.0 L/min, the nebulizer pressure was 30 psi, dry gas
temperature was 350°C, and the Vcap voltage was 3500 V. Data was acquired from the
and processed by the Agilent LC/MSD ChemStation software.

4.3
4.3.1

Results

TLC:
Four

different

solvent

systems

were

evaluated

for

the

separation:

chloroform/methanol (9:1), butanol:acetic acid:water (7:1:2), acetone:ethanol (1:1) and
ethyl acetate:methanol (1:1) (Figure 4.1). Better separation was achieved with
chloroform/methanol with 10 bands resolved on the TLC plate. Separation was also good
on the butanol/acetic/acid/water plate, while the other two solvent systems did not yield
satisfactory separation.
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*
#

*
*
*
a

b

c

d

Figure 4.1: TLC separation of goldenseal leaf extract using (a) ethyl acetate:methanol,
(b) acetone:ethanol, (c) butanol:acetic acid/water and (d) (c) chloroform:
methanol
* band of berberine
# hydrastine (identified by GC/MS)

Separation of goldenseal leaf extract yielded in the appearance of 10 bands with
the chloroform:methanol (9:1) solvent system. The third band (Rf =0.4) was the berberine
alkaloid and the seventh band (Rf =0.76) was identified by GC/MS analysis as the
hydrastine alkaloid.
4.3.2

TLC Bioautography:
Triphenyl tetrazolium chloride (TTC) salt is a dehydrogenase sensitive

compound. The dehydrogenases produced by live cells convert TTC to a brightly colored
formazon. This property helps in observing the clear zone-of-inhibition which resulted
from cell death due to antimicrobial activity by individual constituents present in

64

goldenseal leaf extract by themselves or in synergy with sub lethal dose of ciprofloxacin
(Figure 4.2).

a

b

c

Figure 4.2: Zone of inhibition (ZOI) of a) goldenseal leaf extract, (b) berberine sulfate
and (c) ciprofloxacin prior to separation
Of all the solvent systems, bacteria were able to grow only on the TLC plates
developed in chloroform:methanol solvent system. Identification of active compounds in
goldenseal leaf extract was not possible on TLC plates developed in the other solvent
systems as the bacteria sprayed on these plates did not survive.
Goldenseal leaf extract showed a ZOI before separation by chloroform/methanol
but no zones of inhibition were observed after separation with chloroform/methanol
(Figure 4.2). Berberine sulfate and ciprofloxacin gave rise to zones of inhibition before
and after development of the TLC plates. TLC plates of goldenseal leaf extract (1.3mg,
2.6mg and 3.9mg) developed in chloroform:methanol then sprayed with bacterial
suspension of NorA over expresser SA1199B, seeded with sub lethal dose of
ciprofloxacin (1µg/mL, one eighth of its MIC) gave rise to 4 ZOIs. These ZOIs were not
caused by the band where berberine typically is located at but other components (Figure
4.3). This was confirmed by developing TLC plates spotted with an equivalent
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concentration of berberine sulfate (0.067mg, 0.134mg and 0.201mg) as to that of the
goldenseal leaf extract.

*

1

*

2

*

3

*

4

Figure 4.3: TLC bioautographic studies of SA1199B:
• Plate 1:SA1199B sprayed on developed TLC plate spotted with goldenseal
leaf extract
• Plate 2: SA1199B + sub lethal dose of ciprofloxacin on developed TLC
plate spotted with goldenseal leaf extract
• Plate 3: SA1199B sprayed on developed TLC plate spotted with beberine
sulfate in equivalent concentration to that in the leaf extract
spotted in earlier plates
• Plate 4: SA1199B + sub lethal dose of ciprofloxacin sprayed on developed
TLC plate spotted with beberine sulfate in equivalent
concentration to that in the leaf extract spotted in earlier plates
* Band of berberine
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ZOIs were also seen on bioautographic TLC plates with other MDR bacteria.
Table 4.1 lists the retention factors (Rf) of the bands around which zones of inhibition
were observed. The number of zones of inhibition was different for different bacteria.

Table 4.1: ZOIs on TLC plates sprayed with indicator
bacteria seeded with sub lethal dose of
ciprofloxacin
Band
1
2
3
4
5

ZOI on SA1199B ZOI on SAK2068
Rf
0.13
Yes
Yes
0.33
Yes
No
0.41
Yes
No
0.58
Yes
Yes
0.66
Yes
Yes
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Berberine

Figure 4.4: Number of ZOIs on SA1199B + sub lethal dose of ciprofloxacin sprayed on
developed TLC plate spotted with goldenseal leaf extract and developed in
chloroform:methanol (9:1)
There were 3 ZOIs seen on TLC plates for SAK2068 (Figure 4.6) when sprayed
with bacterial suspension seeded with sub lethal dose of ciprofloxacin. No ZOIs were
observed when the developed TLC plate was sprayed with RN4220 seeded with sub
lethal dose of ciprofloxacin.
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ZOI-5
ZOI-4

Berberine
ZOI-1

Figure 4.5: TLC bioautographic studies of SAK2068:
• Plate 1: SAK2068 sprayed on developed TLC plate spotted with
goldenseal leaf extract
• Plate 2: SAK2068+ sub lethal dose of ciprofloxacin on developed TLC
plate spotted with goldenseal leaf extract

4.3.3

GC/MS:
The five active bands (Figure 4.4) isolated from the TLC plate developed in

chloroform:methanol were analyzed in GC/MS. The presence of hydrastine (band 7 on
TLC) in the goldenseal leaf extract was confirmed by the GC/MS. No other compounds
were detected by GC/MS possibly due to lack of volatility of the compounds.
4.3.4

LC/MS:

*

*

In the spectra of LC/MS
1 analysis of bands
2 causing ZOI on the TLC plate, more
than one compound appeared to be present in the samples. The list of possible
compounds associated with ZOI bands, with their retention time, is given in Table 4.2.
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Table 4.2: List of compounds predicted by LC/MS data
Peak
1
ZOI-1

2

1

ZOI-2
2

ZOI-3

0

ZOI-4

1

ZOI-5

1

Retention List of possible compounds
time
5.349
1. Oxayohimban-16-carboxylic acid,
min
16,17-didehydro-19-methyl-, methyl
ester, (19α)-(ajmalicine)
2. 2H-1-Benzopyran-2-one, 7-hydroxy-6methoxy-3-[(2-oxo-2H-1-benzopyran7-yl)oxy]- (coumarin)
6.576
1. 2,6-Pyridinedicarboxylic acid, 4-[2min
(2,3-dihydro-1H-indol-1-yl)ethenyl]-,
dimethyl ester, (E)- (9CI) (betalain)
5.929
1. (E)-Secocholest-1(10)-EN-3,5- Dione
min
2. Tricyclo[10.2.2.25,8]octadeca5,7,12,14,15,17-hexaene-6,17diacetonitrile, 13,15bis(dimethylamino)-, stereoisomer
9.173
1. Estra-1,3,5(10)-trien-17-one, 3,11min
bis[(trimethylsilyl)oxy]-, (11β)- (9CI)
2. 5, 10-dihexyl-5, 10-dihydroindolo[3, 2B]
3. 1(3H)-Isobenzofuranone, 3,3'-(4,6dimethoxy-1,3-phenylene)bis[3methyl- (9CI)
4. Dimethyl 2-(1’, 4’-dimethoxy-9’, 10’ dioxo
No peaks were observed in the third band
during LC/MS analysis
9.161
1. 2-[3-methyl-6-(1-methylethenyl)-2min
cyclohexan
9.234
1. 13-oxa-16-azamin
hexacyclo[9.6.3.2.[4.7]0[1
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CAS
number
483-04-5
2034-697

9427240-9
8738704-0

6968838-6
6404252-0
-

-

4.4

Discussion

The TLC bioautographic studies clearly indicated that one or more constituents in
goldenseal leaf extract act in synergy with ciprofloxacin in increasing its potency towards
MDR bacteria. The MDR strains SA1199B (NorA) and SAK2068 (MepA) showed ZOIs
on the developed TLC plates spotted with goldenseal leaf extract, then sprayed with sub
lethal dose of ciprofloxacin and indicator bacteria. No ZOI was exhibited by the RN4220
strain which might be due to the fact that the concentration of the potential EPI might not
be enough or the synergistic activity is due to more than one component.
None of these constituents which caused the ZOIs could be detected by GC/MS,
possibly due to the volatility of the compounds, as they might be non-volatile and many
of the active components of goldenseal cannot be analyzed using GC/MS. Berberine is
one such example which cannot be detected by GC/MC (Weber H, 2003). Further
analysis involving derivitization of these compounds is involved in order to assay using
GC/MS.
The samples detected by LCMS had one or more peaks typical to the presence of
one or more compounds. Most notable of these is the alkaloid ajmalicine, produced by
many other plants such as Rauwolfia serpentina (Bein, 1956). One interesting fact to be
noted is that reserpine is also an alkaloid produced by the Rauwolfia sps (Saxena, 2009).
The anti tumor properties of ajmalicine has been evaluated by one group (Xiuwei, 2009).
Another compound, estra, is known to be used as a contraceptive. Coumarin another
compound detected by LC/MS, has been reported for its anticoagulatory properties and
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its potential application in medicine (Wang, 2006). Another compound betalain, used as a
red colored dye, is also being investigated for its anti-tumor activity (Zakharova, 2000).
The other compounds which could not be identified by LC/MS need to be further
analyzed as they could be derivatives of some known compounds and their activity
assayed.
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Conclusion

Multi-drug-resistance due to efflux pumps in bacteria has become an important
problem that needs to be addressed urgently. The study of efflux pump inhibitors
suggests new applications in the treatment of multi-drug-resistant bacterial infections.
Several efflux pump inhibitors have been identified, some are being investigated on
clinical trials and some cannot be used due to harmful side effects. The identification and
development of safe and effective inhibitors of bacterial efflux pumps is needed. Plants
can be excellent sources for efflux pump inhibitors and this source needs to be
investigated thoroughly for the identification of potential efflux pump inhibitors.
Alternative therapy for the treatment of infections caused by different micro organisms
has been applied since ancient times, especially using phytochemicals. Goldenseal is one
such phytochemical which has been used for different ailments.
The goal of this project is to evaluate the antimicrobial activity and possible
multi-drug efflux pump inhibitory effects of crude grain alcohol goldenseal leaf extract.
The antimicrobial properties of the goldenseal leaf extract were determined. It is evident
that one or more constituents in the extract work in synergy to produce the antimicrobial
effect. It is also evident that L. acidophilus, a human intestinal beneficial bacterium,
although equally susceptible to berberine, ciprofloxacin, and reserpine when compared to
the pathogens evaluated, it is much less susceptible to goldenseal. This is favorable since
the impacts on the beneficial microflora exerted by therapeutic agents should be
minimized. The efflux pump inhibitory activities of goldenseal leaf extract were
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evaluated with results indicating that goldenseal leaf extract increases the susceptibility
of the MDR bacteria towards various antimicrobials. Some of these bacteria overexpress
MDR pumps which belong to different MDR pump superfamilies. Goldenseal leaf extract
effectively decreased the MIC of ciprofloxacin against the pumps NorA (MFS) and
MepA (MATE) in S. aureus (≥ 4 folds) and CmeABC (RND) in C. jejuni (16 folds).
Synergy studies of the goldenseal leaf extract clearly indicate that it represses the
genes encoding for these MDR efflux pumps, which is in contrast to that of reserpine.
Reserpine shows a very limited or no gene repression of these MDR pumps. These
synergy studies also indicate that reserpine inhibits the protein MDR pump by interfering
with its function and goldenseal leaf extract does not show this property. This property of
goldenseal leaf extract has to be further evaluated as it is the balanced overall effects of
its constituents rather than the effects of individual constituent are being observed.
Subsequent isolation, and evaluation of purified individual constituent is required for
insight into the mechanism of action in order to optimize the use of such agents to
overcome multi-drug resistance.
The resistance of C. jejuni to multiple drugs is not due to its overexpression of
CmeABC pumps (Mamelli, 2005) but it may work in synergy with other mutations to
confer the resistance. Goldenseal leaf extract seems to overcome all these factors since it
effectively decreases the MIC of ciprofloxacin and erythromycin by at least 2 folds. It
also decreases the MIC of erythromycin in the MsrA pump (RND) carrying strain of S.
aureus by at least 2 folds. As previously mentioned, no EPI that inhibits the MsrA pump
efflux has been identified until recently (Kaatz, 2007). Kaatz et al have identified a
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compound diterpene totarol which they have shown to inhibit MsrA efflux. Goldenseal
leaf extract shows an efflux pump inhibitory activity against both the RND pumps used in
this study, i.e., MsrA of S. aureus and CmeABC of C. jejuni. The positive control used
for the efflux pump inhibitory activity, reserpine did not inhibit either of these pumps.
Lastly, an initial separation and identification of the constituent(s) responsible for
this behavior was attempted. The TLC bioautographic studies indicated more than one
band that showed a possible anti efflux pump activity against the NorA (MFS) and MepA
(MATE) pump carrying strains of S. aureus. No active bands could be isolated with the
MsrA pump strain of S. aureus, indicating that one or more constituents maybe acting
together to show the inhibition.
Further studies are needed to purify, identify, and characterize these specific
constituents. The evaluation and characterization of these individual constituents could
lead to the development of combination therapies that combine goldenseal constituents
and therapeutic agents with improved antimicrobial qualities, i.e., increased potency with
reduced side effects, for use in clinical trials to treat multi-drug resistant bacterial
infections.
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